Neumora Secures $500M, Amgen Deal, in Quest for Precision Neuroscience R&D

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Investing in Manufacturing, Mental Health & More: Bob Nelsen on The Long Run
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?
Who Is Poised To Go Public in 2015, and Who Isn’t?